论文部分内容阅读
目的探讨临床上使用阿替普酶溶栓治疗急性ST段抬高型心肌梗死患者的实际疗效。方法我们对2016年3月~2016年12月期间来我院进行就诊治疗的36例急性ST段抬高型心肌梗死(STEMI)患者的临床资料进行回顾性研究。随机将这36例患者分为实验组和对照组,每组各有18例患者。治疗方式为:实验组静脉滴注阿替普酶,对照组静脉滴注尿激酶。之后对比观察这两组患者的治疗效果及患者发生并发症的情况。结果经过治疗与观察分析,我们发现实验组患者好的溶栓再通效果较另一组明显要好,患者心电图显示其ST段回落程度较大,效果更优,相比之下差异明显,具有统计学意义(P<0.05);实验组患者发生并发症的人数明显要少于对照组患者,二者相比差异显著,具有统计学意义(P<0.05)。结论临床上使用阿替普酶溶栓治疗急性ST段抬高型心肌梗死患者的实际疗效显著,患者的症状明显改善且不会出现不良反应,此方法值得在今后的临床工作中进一步推广应用。
Objective To investigate the clinical efficacy of alteplase thrombolysis in patients with acute ST-segment elevation myocardial infarction. Methods We retrospectively reviewed the clinical data of 36 patients with acute ST-elevation myocardial infarction (STEMI) treated in our hospital from March 2016 to December 2016. The 36 patients were randomly divided into experimental group and control group, each with 18 patients. Treatment methods: experimental group intravenous infusion of alteplase, control group intravenous infusion of urokinase. After comparing the two groups of patients observed the effect of treatment and patients with complications. Results After treatment and observation, we found that the effect of thrombolytic recanalization in the experimental group was significantly better than that of the other group. The electrocardiogram showed that the ST segment of the experimental group dropped back to a larger extent with better effect, compared with the obvious difference (P <0.05). The incidence of complications in the experimental group was significantly less than that in the control group. There was significant difference between the two groups (P <0.05). Conclusion The clinical efficacy of alteplase thrombolysis in patients with acute ST-segment elevation myocardial infarction was significantly improved. The symptoms of patients with acute ST-segment elevation myocardial infarction were significantly improved without any adverse reactions. This method is worthy of further application in future clinical work.